Xiamen Amoytop Biotech Co. Ltd.

  • Market Cap: Large Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CNE100003RT3
CNY
76.54
2.44 (3.29%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

1

The company has declared Positive results for the last 18 consecutive quarters

  • INTEREST COVERAGE RATIO(Q) The company hardly has any interest cost
  • NET SALES(Q) Highest at CNY 1,216.02 MM
  • OPERATING PROFIT(Q) Highest at CNY 472.2 MM
2

With ROE of 34.50%, it has a fair valuation with a 12.11 Price to Book Value

3

Underperformed the market in the last 1 year

stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

CNY 29,448 Million (Large Cap)

stock-summary
P/E

35.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.86%

stock-summary
Debt Equity

-0.23

stock-summary
Return on Equity

30.00%

stock-summary
Price to Book

8.52

Revenue and Profits:
Net Sales:
1,216 Million
(Quarterly Results - Dec 2025)
Net Profit:
372 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-1.66%
0%
-1.66%
6 Months
-10.07%
0%
-10.07%
1 Year
-9.63%
0%
-9.63%
2 Years
31.65%
0%
31.65%
3 Years
67.12%
0%
67.12%
4 Years
177.22%
0%
177.22%
5 Years
112.61%
0%
112.61%

Xiamen Amoytop Biotech Co. Ltd. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
35.99%
EBIT Growth (5y)
54.60%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.29
Sales to Capital Employed (avg)
1.11
Tax Ratio
10.37%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
40.89%
ROE (avg)
22.33%

Valuation key factors

Factor
Value
P/E Ratio
35
Industry P/E
Price to Book Value
12.11
EV to EBIT
31.38
EV to EBITDA
28.56
EV to Capital Employed
15.64
EV to Sales
10.47
PEG Ratio
0.78
Dividend Yield
0.76%
ROCE (Latest)
49.85%
ROE (Latest)
34.50%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 25.50% vs 15.72% in Sep 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 56.00% vs -3.09% in Sep 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,216.00",
          "val2": "968.90",
          "chgp": "25.50%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "472.20",
          "val2": "272.20",
          "chgp": "73.48%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.40",
          "chgp": "-100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.50",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "371.60",
          "val2": "238.20",
          "chgp": "56.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "388.30%",
          "val2": "280.90%",
          "chgp": "10.74%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 31.69% vs 34.33% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 25.39% vs 49.01% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "3,695.60",
          "val2": "2,806.30",
          "chgp": "31.69%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "1,253.60",
          "val2": "1,023.40",
          "chgp": "22.49%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.60",
          "chgp": "-100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.90",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "1,037.70",
          "val2": "827.60",
          "chgp": "25.39%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "339.20%",
          "val2": "331.40%",
          "chgp": "0.78%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQstock-summary

Dec'25
Sep'25
Change(%)
Net Sales
1,216.00
968.90
25.50%
Operating Profit (PBDIT) excl Other Income
472.20
272.20
73.48%
Interest
0.00
0.40
-100.00%
Exceptional Items
0.00
0.50
-100.00%
Consolidate Net Profit
371.60
238.20
56.00%
Operating Profit Margin (Excl OI)
388.30%
280.90%
10.74%
USD in Million.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Dec 2025 is 25.50% vs 15.72% in Sep 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Dec 2025 is 56.00% vs -3.09% in Sep 2025

Annual Results Snapshot (Consolidated) - Dec'25stock-summary

Dec'25
Dec'24
Change(%)
Net Sales
3,695.60
2,806.30
31.69%
Operating Profit (PBDIT) excl Other Income
1,253.60
1,023.40
22.49%
Interest
0.00
0.60
-100.00%
Exceptional Items
0.00
0.90
-100.00%
Consolidate Net Profit
1,037.70
827.60
25.39%
Operating Profit Margin (Excl OI)
339.20%
331.40%
0.78%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2025 is 31.69% vs 34.33% in Dec 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 25.39% vs 49.01% in Dec 2024

stock-summaryCompany CV
About Xiamen Amoytop Biotech Co. Ltd. stock-summary
stock-summary
Xiamen Amoytop Biotech Co. Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available